Citizens Jmp Reiterates Market Outperform Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating restated by stock analysts at Citizens Jmp in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $24.00 target price on the stock. Citizens Jmp’s price target would indicate a potential upside of 164.70% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a report on Monday. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Mizuho decreased their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Stock Up 0.2%

NASDAQ:KURA traded up $0.02 during mid-day trading on Monday, reaching $9.07. The company’s stock had a trading volume of 136,351 shares, compared to its average volume of 1,571,797. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology has a 1 year low of $5.45 and a 1 year high of $12.49. The stock has a fifty day moving average of $9.31 and a 200-day moving average of $9.31. The firm has a market capitalization of $804.88 million, a PE ratio of -2.71 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The business had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Equities research analysts forecast that Kura Oncology will post -3.47 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of the company. IFP Advisors Inc grew its holdings in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP boosted its position in shares of Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after buying an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after buying an additional 9,958 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.